SCHEDULE: Lilly Endowment Maintains 9.8% Stake in Eli Lilly

Lilly Endowment, Inc. filed an amended Schedule 13G, disclosing a continued beneficial ownership of 9.8% of Eli Lilly and Company's common stock as of December 31, 2025.

Summary

• Lilly Endowment, Inc. reported beneficial ownership of 92,190,516 shares of Eli Lilly and Company common stock.
• This ownership represents 9.8% of the total class of securities outstanding.
• The percentage is calculated based on 945,383,757 shares of common stock outstanding as of October 27, 2025, as reported in Eli Lilly's Form 10-Q for the period ended September 30, 2025.
• Lilly Endowment, Inc. holds sole voting power and sole dispositive power over all 92,190,516 shares.
• Lilly Endowment, Inc. is an Indiana-based not-for-profit corporation, classified as a private foundation under Section 509(a) of the Internal Revenue Code.

Sentiment

Score: 5

Explanation: This is a routine disclosure of beneficial ownership, indicating a stable, long-term institutional holding. It does not contain new operational or financial performance data, thus maintaining a neutral sentiment.

Future Outlook

NA

Industry Context

This filing is a routine disclosure of a significant institutional ownership stake in a major pharmaceutical company. Lilly Endowment, Inc. has a long-standing relationship with Eli Lilly and Company, given its historical ties to the Lilly family, making its substantial ownership a consistent feature in the company's ownership structure. Such a large, stable institutional holder can contribute to long-term stability in the company's shareholder base.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant, long-term institutional holder's stake, which can contribute to market stability.

Key Dates

Keywords

Eli Lilly, Lilly Endowment, Schedule 13G, Beneficial Ownership, Common Stock, Pharmaceuticals, Institutional Ownership, Equity Stake